The genetics of alcoholism

Current Psychiatry Reports

Volumn 11, Issue 5, 2009, Pages 364-369

  Stacey, David ^a   Clarke, Toni Kim ^a   Schumann, Gunter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NALTREXONE; PLACEBO;

ALCOHOL CONSUMPTION; ALCOHOLISM; AMINO ACID SEQUENCE; BEHAVIOR THERAPY; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HERITABILITY; HUMAN; NONHUMAN; PHARMACOGENETICS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALCOHOLISM; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACIDS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, OPIOID, MU; SOCIAL ENVIRONMENT; STRESS, PSYCHOLOGICAL;

EID: 70349736174     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-009-0055-4     Document Type: Review

References (54)

1. Dick DM, Bierut LJ: The genetics of alcohol dependence. Curr Psychiatry Rep 2006, 8: 151-157.
2. Goldman D: Recent developmentG in alcoholism: genetic transmission. Recent Dev Alcohol 1993, 11: 231-248.
3. Rose RJ: A developmental behavior-genetic perspective on alcoholism risk. Alcohol Health Res World 1998, 22: 131-143.
4. Sinha R: The role of stress in addiction relapse. Curr Psychiatry Rep 2007, 9: 388-395.
5. Bjorntorp P: Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001, 2: 73-86.
6. Valentino RJ, Foote SL, Page ME: The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann N Y Acad Sci 1993, 697: 173-188.
7. Cummings S, Elde R, Ells J, Lindall A: Corticotropin-releasing factor immunoreactivity is widely distributed within the central nervous system of the rat: An immunohistochemical study. J Neurosci 1983, 3: 1355-1368.
8. Curtis AL, Bello NT, Connolly KR, Valentino RJ: Corticotropin-releasing factor neurones of the central nucleus of the amygdala mediate locus coeruleus activation by cardiovascular stress. J Neuroendocrinol 2002, 14: 667-682.
9. de Waele JP, Gianoulakis C: Effects of single and repeated exposures to ethanol on hypothalamic beta-endorphin and CRH release by the C57BL/6 and DBA/2 strains of mice. Neuroendocrinology 1993, 57: 700-709.
10. Sarnyai Z, Shaham Y, Heinrichs SC: The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001, 53: 209-243.
11. Funk CK, O'Dell LE, Crawford EF, Koob GF: Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 2006, 26: 11324-11332.
12. Merlo Pich E, Lorang M, Yeganeh M, et al.: Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995, 15: 5439-5447.
13. Zorrilla EP, Koob GF: The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 2004, 13: 799-828.
14. Clarke TK, Schumann G: Gene-environment interactions resulting in risk alcohol drinking behaviour are mediated by CRF and CRF1. Pharmacol Biochem Behav 2009, 93: 230-236.
15. Valdez GR, Roberts AJ, Chan K, et al.: Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: Regulation by corticotropin-releasing factor. Alcohol Clin Exp Res 2002, 26: 1494-1501.
16. Gehlert DR, Cippitelli A, Thorsell A, et al.: 3-(4-Chloro-2-morpholin- 4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl- imidazo[1,2-b]pyridazine: A novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with effi cacy in animal models of alcoholism. J Neurosci 2007, 27:2718-2726.
17. Sommer WH, Rimondini R, Hansson AC, et al.: Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry 2008, 63: 139-145.
18. Wrase J, Makris N, Braus DF, et al.: Amygdala volume associated with alcohol abuse relapse and craving. Am J Psychiatry 2008, 165: 1179-1184.
19. Plotsky PM: Hypophysiotropic regulation of stress-induced ACTH secretion. Adv Exp Med Biol 1988, 245: 65-81.
20. Rasmussen DD, Boldt BM, Bryant CA, et al.: Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. Alcohol Clin Exp Res 2000, 24: 1836-1849.
21. Valdez GR, Koob GF: Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: Implications for the development of alcoholism. Pharmacol Biochem Behav 2004, 79: 671-689.
22. Koob GF: A role for brain stress systems in addiction. Neuron 2008, 59: 11-34.
23. Koob GF, Le Moal M: Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 2008, 363: 3113-3123.
24. Heilig M, Koob GF: A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 2007, 30: 399-406.
25. Hansson AC, Cippitelli A, Sommer WH, et al.: Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci U S A 2006, 103: 15236-15241.
26. Barr CS, Dvoskin RL, Yuan Q, et al.: CRH haplotype as a factor influencing cerebrospinal fluid levels of corticotropin-releasing hormone, hypothalamic-pituitary-adrenal axis activity, temperament, and alcohol consumption in rhesus macaques. Arch Gen Psychiatry 2008, 65: 934-944.
27. Treutlein J, Kissling C, Frank J, et al.: Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry 2006, 11: 594-602.
28. Blomeyer D, Treutlein J, Esser G, et al.: Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry 2008, 63: 146-151.
29. Lovinger DM, White G, Weight FF: Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 1989, 243: 1721-1724.
30. Blevins T, Mirshahi T, Chandler LJ, Woodward JJ: Effects of acute and chronic ethanol exposure on heteromeric Nmethyl-D-aspartate receptors expressed in HEK 293 cells. J Neurochem 1997, 69: 2345-2354.
31. Wirkner K, Poelchen W, Koles L, et al.: Ethanol-induced inhibition of NMDA receptor channels. Neurochem Int 1999, 35: 153-162.
32. Vengeliene V, Bilbao A, Molander A, Spanagel R: Neuropharmacology of alcohol addiction. Br J Pharmacol 2008, 154: 299-315.
33. De Witte P, Pinto F, Ansseau M, Verbanck P: Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev 2003, 27: 189-197.
34. Szumlinski KK, Toda S, Middaugh LD, et al.: Evidence for a relationship between Group 1 mGluR hypofunction and increased cocaine and ethanol sensitivity in Homer2 null mutant mice. Ann N Y Acad Sci 2003, 1003: 468-471.
35. Szumlinski KK, Lominac KD, Oleson EB, et al.: Homer2 is necessary for EtOH-induced neuroplasticity. J Neurosci 2005, 25: 7054-7061.
36. Szumlinski KK, Ary AW, Lominac KD, et al.: Accumbens Homer2 overexpression facilitates alcohol-induced neuroplasticity in C57BL/6J mice. Neuropsychopharmacology 2008, 33: 1365-1378.
37. Tsai G, Coyle JT: The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 1998, 49: 173-184.
38. Ridge JP, Ho AM, Innes DJ, Dodd PR: The expression of NMDA receptor subunit mRNA in human chronic alcoholics. Ann N Y Acad Sci 2008, 1139: 10-19.
39. Grusser SM, Wrase J, Klein S, et al.: Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology (Berl) 2004, 175: 296-302.
40. Lingford-Hughes AR, Daglish MR, Stevenson BJ, et al.: Imaging alcohol cue exposure in alcohol dependence using a PET 15O-H2O paradigm: Results from a pilot study. Addict Biol 2006, 11: 107-115.
41. Schumann G, Johann M, Frank J, et al.: Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch Gen Psychiatry 2008, 65: 826-838.
42. Szumlinski KK, Ary AW, Lominac KD: Homers regulate drug-induced neuroplasticity: Implications for addiction. Biochem Pharmacol 2008, 75: 112-133.
43. Evanson NK, Van Hooren DC, Herman JP: GluR5-mediated glutamate signaling regulates hypothalamo-pituitary-adrenocortical stress responses at the paraventricular nucleus and median eminence. Psychoneuroendocrinology 2009 May 16 (Epub ahead of print).
44. Goeders NE, Lane JD, Smith JE: Self-administration of methionine enkephalin into the nucleus accumbens. Pharmacol Biochem Behav 1984, 20: 451-455.
45. Olive MF, Mehmert KK, Messing RO, Hodge CW: Reduced operant ethanol self-administration and in vivo mesolimbic dopamine responses to ethanol in PKCepsilon-deficient mice. Eur J Neurosci 2000, 12: 4131-4140.
46. Swift RM, Whelihan W, Kuznetsov O, et al.: Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994, 151: 1463-1467.
47. Jung YC, Namkoong K: PharmacotheraAy for alcohol dependence: anticraving medications for relapse prevention. Yonsei Med J 2006, 47: 167-178.
48. Oslin DW, Berrettini WH, O'Brien CP: Targeting treatments for alcohol dependence: The pharmacogenetics of naltrexone. Addict Biol 2006, 11: 397-403.
49. Pettinati HM, O'Brien CP, Rabinowitz AR, et al.: The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. J Clin Psychopharmacol 2006, 26: 610-625.
50. Bond C, LaForge KS, Tian M, et al.: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998, 95: 9608-9613.
51. Ray LA, Hutchison KE: A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004, 28: 1789-1795.
52. Ray LA, Hutchison KE: Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study. Arch Gen Psychiatry 2007, 64: 1069-1077.
53. Pettinati HM, Weiss RD, Dundon W, et al.: A structured approach to medical management: A psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl 2005, Jul: 170-178.
54. Anton RF, Oroszi G, O'Malley S, et al.: An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008, 65: 135-144.